Does the media favor AVIR or ANIP?

In the previous week, ANI Pharmaceuticals had 6 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 7 mentions for ANI Pharmaceuticals and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.13 beat ANI Pharmaceuticals' score of 0.67 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ANI Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has higher valuation and earnings, AVLN or AVIR?

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A -$22.81 N/A Atea Pharmaceuticals N/A N/A -$158.35M -$2.08 N/A

Is AVLN or AVIR more profitable?

Avalyn Pharma's return on equity of 0.00% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Avalyn Pharma N/A N/A N/A Atea Pharmaceuticals N/A -64.25% -57.12%

Does the media refer more to AVLN or AVIR?

In the previous week, Avalyn Pharma had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for Avalyn Pharma and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.13 beat Avalyn Pharma's score of 0.77 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer XERS or AVIR?

In the previous week, Xeris Biopharma had 7 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 8 mentions for Xeris Biopharma and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.13 beat Xeris Biopharma's score of 0.95 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PAHC or AVIR?

In the previous week, Phibro Animal Health had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 2 mentions for Phibro Animal Health and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.13 beat Phibro Animal Health's score of 0.50 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, AVIR or LBRX?

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Atea Pharmaceuticals N/A N/A -$158.35M -$2.08 N/A LB Pharmaceuticals N/A N/A -$25.20M -$3.44 N/A

Is AVIR or LBRX more profitable?

LB Pharmaceuticals' return on equity of -25.92% beat Atea Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Atea Pharmaceuticals N/A -64.25% -57.12% LB Pharmaceuticals N/A -25.92% -24.68%

Does the media favor AVIR or LBRX?

In the previous week, LB Pharmaceuticals had 7 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 8 mentions for LB Pharmaceuticals and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.13 beat LB Pharmaceuticals' score of 0.22 indicating that Atea Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LB Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Atea Pharmaceuticals (AVIR) Competitors

$5.27 -0.41 (-7.22%)

Closing price 04:00 PM Eastern

Extended Trading

$5.22 -0.05 (-0.95%)

As of 07:30 PM Eastern

Compare

AVIR vs. ANIP, AVLN, XERS, PAHC, and LBRX

Should you buy Atea Pharmaceuticals stock or one of its competitors? Atea Pharmaceuticals's main competitors and comparable companies include ANI Pharmaceuticals (ANIP), Avalyn Pharma (AVLN), Xeris Biopharma (XERS), Phibro Animal Health (PAHC), and LB Pharmaceuticals (LBRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Atea Pharmaceuticals compare to ANI Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

ANI Pharmaceuticals has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than ANI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A
ANI Pharmaceuticals	$883.37M	1.84	$78.34M	$4.64	15.24

Atea Pharmaceuticals currently has a consensus price target of $7.00, suggesting a potential upside of 32.83%. ANI Pharmaceuticals has a consensus price target of $105.57, suggesting a potential upside of 49.32%. Given ANI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
ANI Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.56

In the previous week, ANI Pharmaceuticals had 6 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 7 mentions for ANI Pharmaceuticals and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.13 beat ANI Pharmaceuticals' score of 0.67 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ANI Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Atea Pharmaceuticals has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, ANI Pharmaceuticals has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

ANI Pharmaceuticals has a net margin of 11.07% compared to Atea Pharmaceuticals' net margin of 0.00%. ANI Pharmaceuticals' return on equity of 27.37% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
ANI Pharmaceuticals	11.07%	27.37%	10.47%

86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 21.6% of Atea Pharmaceuticals shares are held by insiders. Comparatively, 8.1% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

ANI Pharmaceuticals beats Atea Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Avalyn Pharma's return on equity of 0.00% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Atea Pharmaceuticals	N/A	-64.25%	-57.12%

Avalyn Pharma currently has a consensus target price of $60.00, suggesting a potential upside of 67.22%. Atea Pharmaceuticals has a consensus target price of $7.00, suggesting a potential upside of 32.83%. Given Avalyn Pharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Avalyn Pharma is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

86.7% of Atea Pharmaceuticals shares are held by institutional investors. 21.6% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Avalyn Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	-$22.81	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A

In the previous week, Avalyn Pharma had 3 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 4 mentions for Avalyn Pharma and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.13 beat Avalyn Pharma's score of 0.77 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Avalyn Pharma beats Atea Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment.

Xeris Biopharma has higher revenue and earnings than Atea Pharmaceuticals. Xeris Biopharma is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	4.82	$550K	-$0.11	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A

Xeris Biopharma presently has a consensus price target of $12.00, suggesting a potential upside of 55.64%. Atea Pharmaceuticals has a consensus price target of $7.00, suggesting a potential upside of 32.83%. Given Xeris Biopharma's higher probable upside, equities analysts clearly believe Xeris Biopharma is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Xeris Biopharma has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

Atea Pharmaceuticals has a net margin of 0.00% compared to Xeris Biopharma's net margin of -5.12%. Xeris Biopharma's return on equity of 338.21% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	-5.12%	338.21%	3.50%
Atea Pharmaceuticals	N/A	-64.25%	-57.12%

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Xeris Biopharma had 7 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 8 mentions for Xeris Biopharma and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.13 beat Xeris Biopharma's score of 0.95 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Xeris Biopharma beats Atea Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to Phibro Animal Health?

Phibro Animal Health (NASDAQ:PAHC) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Phibro Animal Health has higher revenue and earnings than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phibro Animal Health	$1.52B	0.98	$99.72M	$2.44	15.08
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A

Phibro Animal Health currently has a consensus target price of $47.67, indicating a potential upside of 29.53%. Atea Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 32.83%. Given Atea Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Atea Pharmaceuticals is more favorable than Phibro Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phibro Animal Health	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

In the previous week, Phibro Animal Health had 1 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 2 mentions for Phibro Animal Health and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.13 beat Phibro Animal Health's score of 0.50 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phibro Animal Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.3% of Phibro Animal Health shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 50.1% of Phibro Animal Health shares are owned by company insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Phibro Animal Health has a net margin of 6.57% compared to Atea Pharmaceuticals' net margin of 0.00%. Phibro Animal Health's return on equity of 37.86% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phibro Animal Health	6.57%	37.86%	9.18%
Atea Pharmaceuticals	N/A	-64.25%	-57.12%

Phibro Animal Health has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

Summary

Phibro Animal Health beats Atea Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Atea Pharmaceuticals compare to LB Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and LB Pharmaceuticals (NASDAQ:LBRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

Atea Pharmaceuticals presently has a consensus target price of $7.00, indicating a potential upside of 32.83%. LB Pharmaceuticals has a consensus target price of $49.63, indicating a potential upside of 4.10%. Given Atea Pharmaceuticals' higher probable upside, equities analysts plainly believe Atea Pharmaceuticals is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$3.44	N/A

In the previous week, LB Pharmaceuticals had 7 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 8 mentions for LB Pharmaceuticals and 1 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.13 beat LB Pharmaceuticals' score of 0.22 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atea Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LB Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 21.6% of Atea Pharmaceuticals shares are owned by company insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

LB Pharmaceuticals' return on equity of -25.92% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-64.25%	-57.12%
LB Pharmaceuticals	N/A	-25.92%	-24.68%

Summary

Atea Pharmaceuticals and LB Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

Get Atea Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVIR vs. The Competition

Export

Metric	Atea Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$455.56M	$12.53B	$7.23B	$12.88B
Dividend Yield	N/A	2.61%	2.55%	9.95%
P/E Ratio	-2.53	794.77	271.78	25.29
Price / Sales	N/A	952.44	709.75	112.40
Price / Cash	N/A	91.31	77.55	52.32
Price / Book	1.49	10.59	10.63	6.26
Net Income	-$158.35M	$2.82B	$3.48B	$357.86M
7 Day Performance	-7.54%	-2.26%	-1.38%	-0.39%
1 Month Performance	0.38%	2.41%	2.17%	-1.28%
1 Year Performance	66.77%	4.77%	20.74%	11.50%

Atea Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVIR Atea Pharmaceuticals	2.086 of 5 stars	$5.27 -7.2%	$7.00 +32.8%	+74.8%	$455.56M	N/A	N/A	70	Positive News
ANIP ANI Pharmaceuticals	3.7944 of 5 stars	$71.92 -1.8%	$105.83 +47.2%	-26.2%	$1.68B	$883.37M	15.50	600	Analyst Forecast
AVLN Avalyn Pharma	3.0567 of 5 stars	$35.28 +1.6%	$60.00 +70.1%	N/A	$1.54B	N/A	N/A	51	News Coverage Positive News Gap Down
XERS Xeris Biopharma	3.7247 of 5 stars	$8.43 -0.1%	$12.00 +42.3%	+9.1%	$1.54B	$291.85M	N/A	290
PAHC Phibro Animal Health	3.0906 of 5 stars	$38.37 +1.7%	$47.67 +24.2%	-5.4%	$1.53B	$1.52B	15.73	2,605

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVIR) was last updated on 9/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. ANIP, AVLN, XERS, PAHC, and LBRX

How does Atea Pharmaceuticals compare to ANI Pharmaceuticals?

Summary

How does Atea Pharmaceuticals compare to Avalyn Pharma?

Summary

How does Atea Pharmaceuticals compare to Xeris Biopharma?

Summary

How does Atea Pharmaceuticals compare to Phibro Animal Health?

Summary

How does Atea Pharmaceuticals compare to LB Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atea Pharmaceuticals (AVIR) Competitors

AVIR vs. ANIP, AVLN, XERS, PAHC, and LBRX

How does Atea Pharmaceuticals compare to ANI Pharmaceuticals?

Which has preferable valuation & earnings, AVIR or ANIP?

Do analysts prefer AVIR or ANIP?

Does the media favor AVIR or ANIP?

Which has more risk & volatility, AVIR or ANIP?

Is AVIR or ANIP more profitable?

Do institutionals & insiders hold more shares of AVIR or ANIP?

Summary

How does Atea Pharmaceuticals compare to Avalyn Pharma?

Is AVLN or AVIR more profitable?

Do analysts prefer AVLN or AVIR?

Do insiders & institutionals hold more shares of AVLN or AVIR?

Which has higher valuation and earnings, AVLN or AVIR?

Does the media refer more to AVLN or AVIR?

Summary

How does Atea Pharmaceuticals compare to Xeris Biopharma?

Which has preferable earnings & valuation, XERS or AVIR?

Do analysts prefer XERS or AVIR?

Which has more risk and volatility, XERS or AVIR?

Is XERS or AVIR more profitable?

Do insiders and institutionals believe in XERS or AVIR?

Does the media prefer XERS or AVIR?

Summary

How does Atea Pharmaceuticals compare to Phibro Animal Health?

Which has better earnings & valuation, PAHC or AVIR?

Do analysts prefer PAHC or AVIR?

Does the media prefer PAHC or AVIR?

Do insiders & institutionals have more ownership in PAHC or AVIR?

Is PAHC or AVIR more profitable?

Which has more volatility & risk, PAHC or AVIR?

Summary

How does Atea Pharmaceuticals compare to LB Pharmaceuticals?

Do analysts recommend AVIR or LBRX?

Which has stronger earnings and valuation, AVIR or LBRX?

Does the media favor AVIR or LBRX?

Do insiders and institutionals believe in AVIR or LBRX?

Is AVIR or LBRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVIR vs. The Competition

Atea Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools